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Further investigations using larger cohorts are warranted to
better understand economic and patient-reported outcomes asso-
ciated with biologic treatment in psoriasis.
PSK3
A COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC THERAPIES
FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
Roberts G1, Morris J2
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OBJECTIVES: Biologic therapies have been shown to be a safe
and effective treatment for chronic plaque psoriasis. However,
there appear to be notable differences in effectiveness between
treatment options. Given the considerable costs of these treat-
ments, their relative cost-effectiveness is an important consider-
ation. METHODS: A cost-effectiveness model was developed to
estimate the incremental cost per responder associated with each
biologic licensed in the UK for psoriasis. Data on response,
deﬁned as Psoriasis Area Severity Index (PASI) 75 or 90, were
derived from randomized controlled trials for efalizumab, etan-
ercept and inﬂiximab. An ordered probit model was used to
model response rates jointly. Treatment effects, deﬁned as
response rates, and direct health care costs from published
sources were modelled over a 1-year time-horizon. Costs
included in the analysis comprised drug acquisition, monitoring
and administration costs, as well as costs associated with out-
patient and inpatient hospital episodes. Treatment non-
responders were assumed to receive best supportive care. All
licensed regimens were included as potential treatment options.
RESULTS: In the analysis utilising PASI 75 response, efaluzimab
and etanercept 25 mg twice weekly (BIW) continuous, were dom-
inated by other regimens. Of the remaining strategies, etanercept
25 mg BIW had the lowest ICER vs. supportive care (response
rate 31.78%, £8891 per responder gained), followed by inﬂix-
imab (78.79%, £11,302) and then etanercept 50 mg continuous,
(45.99%, £12,598). For PASI 90 response, the same two strate-
gies were dominated. However inﬂiximab was the most effective
and had the lowest ICER vs. supportive care (response rate
56.65%, £15,721 per responder gained) followed by etanercept
25 mg BIW (12.34%, £22,907) then etanercept 50 mg continu-
ous, (21.58%, £26,853). CONCLUSIONS: Provided decision-
makers are willing to pay up to approximately £12,000 to gain
an additional PASI 75 responder and also value clearance of
symptoms (PASI 90 responder), treatment with inﬂiximab is




COMPOUND PRODUCT IN A SCOTTISH CARE MODEL
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OBJECTIVES: UVB phototherapy is an effective treatment for
psoriasis, typically introduced after a patient with widespread
disease has failed to respond to a couple of topical agents. A
pharmacoeconomic model was devised to analyse the cost impli-
cations of different treatment combinations based on a Scottish
model of care. METHODS: A calcipotriol/betamethasone dipro-
pionate two-compound product was assessed alongside two of
the UK’s most commonly prescribed topical antipsoriatic agents
(calcipotriol and betamethasone valerate in several different
treatment regimens to determine the most cost-effective treat-
ment A Markov chain approach was used to model the pro-
gression of psoriatic patients through the response or non-
response to 4 weeks treatment with different topical agents. The
patient pathway consisted of two four-week treatments with ﬁrst
and second line topical agents before referral to secondary care
and phototherapy. Non-responders (i.e. those who did not
achieve PASI-75) on ﬁrst line treatment were then given a second
line topical agent. Those who failed again were referred to sec-
ondary care and waited 6 months before completing 20 treat-
ments of phototherapy. One hundred patients were evaluated in
each of the six different treatment pathways over one year to
determine overall cost per patient. RESULTS: Mean annual cost
per patient showed that the most cost-effective treatment
regimen used the two compound product as ﬁrst and second line
treatments. It was 19.7% cheaper (≤690.99 vs ≤860.62) and
32% fewer patients required phototherapy (30 vs 44) when com-
pared to the next best regimen which used the two-compound
product and calcipotriol as ﬁrst and second line treatments
respectively. CONCLUSION: This pharmacoeconomic evalua-
tion demonstrates that the two-compound product, when used
as an initial therapy in psoriasis, could result in a reduction in
overall costs per patient and in fewer patients requiring pho-
totherapy. This in turn, could improve access to phototherapy
for more patients with light-responsive dermatoses.
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OBJECTIVES: The aim of the Costi-&-Outcomes-in-Dermatite-
Atopica (CODA) study was to evaluate the socioeconomic
impact of AD. METHODS: The CODA study was a naturalis-
tic, multicentre, longitudinal ambispective (retro-prospective),
prevalence based Cost Of Illness study. Data on patients with
moderate or severe AD enrolled during ﬂare-up was collected:
socio-demographic, clinical (SCORing-Atopic-Dermatitis index
(SCORAD): 0 = no disease; 100 = maximum manifestation) eco-
nomic (direct and indirect costs), HRQoL (intangible costs),
preferences towards pharmacological treatment. The following
results pertain to the economic burden of AD and its treatment
in adult patients. The analysis was conducted from the societal
perspective with a 3 month time horizon. Direct medical costs
(hospitalizations, drugs, cosmetics, personal health supplies, spe-
cialist visits, diagnostics and laboratory exams) were quantiﬁed
using prices or tariffs expressed in Euro 2005. Also indirect cost,
in terms of productivity losses by patients, were calculated using
human capital approach. RESULTS: We erolled 104 valid adults
from 6 Italian dermatological referral centres (males 53.8%,
mean age = 32.9 ± 11.8 y.o.). At the enrolment the median
SCORAD was 52.0 while after 2 months was 18.0 (p < 0.0001
Wilcoxon Signed Rank test). Direct cost/patient/month was at
baseline 369.6 ± 440.0€: 28.8% hospitalizations, 19.9% drugs,
16.0% cosmetics. After 2 months from the enrolment direct
cost/patient/month was €188.1 ± €236.1: 42.5% drugs, 35.2%
cosmetics, 8.8% hospitalizations. The decrease in direct cost
during the follow up period was statistically signiﬁcant (p = <
0.0001 paired samples t test). Indirect cost/patient/month was
€247.0 ± €626.5 at baseline and €32.8 ± €106.1 after 2 months
(p = < 0.0001). CONCLUSION: This is the ﬁrst study evaluat-
ing the socio-economic impact of AD in Italy. The difference
between cost during relapse period and after 2 months is signif-
icant. Among adult patients hospitalisations and drugs are the
cost drivers at baseline and after 2 months respectively. High cost
A268 Abstracts
and the sensitive impairment of quality of life signiﬁcantly con-
tribute to the high socioeconomic burden of AD.
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BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN
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OBJECTIVES: To assess the impacts of Elidel® (pimecrolimus)
cream 1% usage, in routine Belgian clinical practice in patients
with mild to moderate atopic dermatitis, in terms of: pime-
crolimus drug consumption; use of topical corticosteroids;
quality of life; and safety. METHODS: An open-label, single
arm, observational, multicenter study with one year follow-up
to cover the seasonality of atopic dermatitis. Yearly pime-
crolimus drug consumption was estimated based on the number
and quantity of delivered prescriptions and on the number of
unused or partially used tubes left at the end of the study. Topical
corticosteroid use was assessed by a steroid usage questionnaire
and the delivered topical corticosteroid prescriptions. Quality of
life was gauged using validated disease speciﬁc instruments, i.e.
the Parents’Index Quality of Life-Atopic Dermatitis (PIQoL-AD)
or the Quality of Life Index-Atopic Dermatitis (QoLIAD),
depending on patient’s age. All adverse events were recorded.
RESULTS: A total of 416 patients were enrolled from 49 study
centers geographically spread over Belgium. For patients who
completed this 12 months study, the mean (SD) amount of pre-
scribed pimecrolimus cream 1% per patient was 120.8 (117.0)
gram per year, with an estimated consumption of 104.4 (117.6)
gram per year. Topical corticosteroids were used before the study
in 81.7% of the population. At the end of study 83.3% of them
stated that they were using less topical corticosteroids when
pimecrolimus is part of their treatment regimen. Mean (SD)
improvements versus baseline in PIQoL-AD and QoLIAD scores
were 34.5% (84.3%) and 31.2% (70.8%), respectively. Median
(IQR) improvements were 50.0% (12.5%–85.7%) and 46.4%
(0.0%–85.0%), respectively. Pimecrolimus also showed good
tolerability proﬁle. CONCLUSIONS: This observational study
showed favorable pimecrolimus proﬁle in routine practice
reﬂected by relatively small amount of drug used, corticosteroid
sparing effect, improvement in quality of life, and good 
tolerability.
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Generic Quality of Life (QoL) instruments are useful to compare
different populations. However these instruments could be crit-
icized for having some drawbacks, and disease-speciﬁc instru-
ments could be preferred to measure those aspects of wellbeing
inﬂuenced by a speciﬁc disease and to effectively measure health
changes over the time. OBJECTIVE: We tested convergent valid-
ity and sensitivity to change over time of a generic and disease-
speciﬁc pediatric questionnaires to evaluate wellbeing in children
with Atopic Dermatitis (AD), a very frequent, chronic and dis-
abling disease. METHODS: Data from the Costi-&-Outcomes-
in-Dermatite-Atopica (CODA) naturalistic, prospective Cost-Of-
Illness study, involving moderate and severe AD patients, were
used. Patients aged 5–16 y.o. and/or their caregivers completed
twice (at ﬂare-up and after 2 months) the KINDL (children-
reported version: KINDL-C, parent-reported version: KINDL-P;
scores = 0–100, higher score = higher QoL) and CDLQI (Chil-
dren’s-Dermatology-Life-Quality-Index, with scores = 0–30,
higher score = lower QoL). Patients’ clinical status was evalu-
ated with the SCORAD index (SCORing-Atopic-Dermatitis,
possible score = 0–100, higher score = higher severity). We tested
convergent validity by investigating correlations between QoL
instruments; sensitivity to change over time was tested with
paired students’ t tests, Standardized Response Mean (SRM),
Effect Size (EF). RESULTS: Pediatric patients were 66, 43.9%
male, median age = 8.8 y.o., median SCORAD at enrolment =
41.5 (3.0–85.0). CDLQI signiﬁcantly correlated with KINDL-P
(Spearman’s r = −0.44 p = 0.001) and KINDL-C (r = −0.36 p =
0.008), KINDL-P sensitively correlated with KINDL-C (r = 0.67
p < 0.0001). At follow-up clinical severity signiﬁcantly decreased
(Student’s paired t test, p < 0.0001). Patients reported signiﬁcant
lower scores of CDLQI (Student’s paired t test, p < 0.05), while
no statistical change was found with KINDL-P and KINDL-C.
SRM and ES were moderate for CDLQI (SRM = 0.44, ES = 0.41)
and low for KINDL-C (SRM = 0.26, ES = 0.26) and KINDL-P
(SRM = 0.12, ES = 0.11). CONCLUSION: KINDL signiﬁcantly
correlated with CDLQI, anyway sensitivity to change results
were moderate to low. Understanding these properties in QoL
questionnaires is necessary to allow their appropriate use and
interpretation of QoL data.
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Generic instruments such as EQ-5D are useful to compare
quality of life (QoL) of different populations and to include QoL
information in health-economic research. However these instru-
ments could be criticized for having some drawbacks, and
disease-speciﬁc instruments could be more capable to measure
those aspects of wellbeing inﬂuenced by a speciﬁc disease and
could be more sensitive to measure health changes over the time.
OBJECTIVE: We tested convergent validity and sensitivity to
change over time of EQ-5D and the Dermatology-Life-Quality-
Index (DLQI, possible scores = 0–30, higher score = lower QoL)
in Atopic Dermatitis (AD), a very frequent, chronic, sensitively
disabling disease. METHODS: Data from the Costi-&-Out-
comes-in-Dermatite-Atopica (CODA) naturalistic, prospective,
Cost-Of-Illness study, involving moderate and severe AD
patients, were used. Socio-demographic, clinical severity (with
SCORAD, SCORing-Atopic-Dermatitis index, possible score =
0–100, higher score = higher severity), economic and QoL data
were collected. Patients from 16 y.o. self-completed twice (at
ﬂare-up and after 2 months) EQ-5D and DLQI. We tested cor-
relation of EQ-5D indexes with DLQI and sensitivity to change
over time of these indexes with paired Students’ t tests, Stan-
dardized Response Mean (SRM), Effect Size (EF). RESULTS:
Patients were 98, 48% male, median age = 30.5 y.o. (18–77). At
enrolment median SCORAD = 53.0 (18.4–90.0), median EQ-
VAS = 65.0 (0.0–95.0), median utility score from EQ-proﬁle =
